|
dexrazoxane
dexrazoxane
information and resources from the National Cancer Institute
NCI Thesaurus | dexrazoxane
A bisdioxopiperazine with antineoplastic activity and cardioprotective properties. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, thereby preventing the metal-catalyzed formation of reactive oxygen radicals produced by anthracycline antibiotics such as doxorubicin. This agent also inhibits the catalytic activity of topoisomerase II, resulting in cell growth inhibition. NCI Thesaurus | dexrazoxane
A bisdioxopiperazine with antineoplastic activity and cardioprotective properties. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, thereby preventing the metal-catalyzed formation of reactive oxygen radicals produced by anthracycline antibiotics such as doxorubicin. This agent also inhibits the catalytic activity of topoisomerase II, resulting in cell growth inhibition.
Zinecard
Accel. Approv. (clinical benefit subsequently established) Prevention of cardiomyopathy associated with doxorubicin administration
Pharmacia & Upjohn Company May 26 1995
Zinecard
reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. It is not recommended for use with the initiation of doxorubicin therapy.
Pharmacia & Upjohn Company Oct 31 2002
|
|
|
|
|
|
dexrazoxane
-->
|
